文献速递神经免疫

间充质干细胞治疗多发性硬化的2期随机双盲交叉试验

Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial.
PubMed 文献 · Lancet Neurol · 2021-01-01

MESEMS为在9国15中心开展的2期随机双盲交叉试验,纳入144例活动性复发缓解型或进展型多发性硬化患者,比较单次静脉输注自体骨髓间充质干细胞与安慰剂的疗效与安全性。

要点

  • 自体骨髓间充质干细胞静脉输注安全、耐受性良好,未见与输注相关严重不良事件。
  • 治疗未减少第4、12、24周钆增强病灶总数,主要疗效终点未达到。
  • 研究不支持用骨髓间充质干细胞治疗活动型多发性硬化,后续应关注组织修复相关指标。

核心结论

  • 骨髓来源间充质干细胞治疗安全且耐受性良好,但在第24周对活动型多发性硬化患者的钆增强病灶无效果,本研究不支持其用于治疗活动型多发性硬化。
  • 后续研究应探讨间充质干细胞对组织修复相关参数的作用。

研究设计与样本

  • MESEMS为随机2期试验,在9个国家15个中心开展,采用交叉设计,按1:1随机分组。
  • 患者先接受单次静脉自体骨髓间充质干细胞后第24周安慰剂,或先安慰剂后第24周间充质干细胞,第48周随访。
  • 共144例随机分组:早期接受间充质干细胞者69例,早期接受安慰剂者75例。

主要发现

  • 共记录213例不良事件,两组分布相似:早期间充质干细胞组69例中35例(51%)记录93例,早期安慰剂组75例中42例(56%)记录120例。
  • 最常见不良事件为感染和侵染,共54例(25%),其中早期间充质干细胞组18例(19%),延迟间充质干细胞组36例(30%)。
  • 安慰剂组7例患者报告9例严重不良事件,间充质干细胞组无严重不良事件;所有严重不良事件均认为与输注无关。
  • 研究期间无死亡报告。

关键数值与推荐

  • 主要疗效终点采用 predefined 统计检验流程评估,在意向治疗全分析集于所有参与者完成第24周访视后评估。
  • 主要安全性终点为各治疗组不良事件的数量和严重程度,每次访视记录生命体征和不良事件。

临床怎么用

  • 对于活动性复发缓解型或进展型多发性硬化,不应以骨髓间充质干细胞作为减少急性炎症病灶的治疗选择。
  • 临床决策时应向患者说明该治疗安全但缺乏MRI病灶活动度获益的证据。
  • 间充质干细胞在组织修复方面的作用仍需进一步研究,不宜据此扩大适应证。

局限性

  • 主要疗效终点为第24周钆增强病灶数,属于急性炎症的MRI替代指标,未评估组织修复或长期残疾进展。
  • 研究采用交叉设计,部分安全性数据按治疗顺序分组呈现,可能影响组间比较的解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mesenchymal stem cells (MSCs), also known as mesenchymal stromal cells, have been proposed as a promising therapeutic option for people with multiple sclerosis on the basis of their immunomodulatory and neuroprotective properties. The MEsenchymal StEm cells for Multiple Sclerosis (MESEMS) study was devised to evaluate the safety, tolerability, and activity of autologous MSCs derived from bone marrow and infused intravenously in patients with active multiple sclerosis. METHODS: MESEMS is a randomised phase 2 trial done at 15 sites in nine countries. Patients (aged 18-50 years) with active relapsing-remitting or progressive multiple sclerosis were included if they had a disease duration of 2-15 years since onset of multiple sclerosis and an Expanded Disability Status Scale score of 2·5-6·5. Patients were randomly assigned (1:1), according to a crossover design, to receive a single intravenous dose of autologous bone marrow-derived MSCs followed by placebo at week 24, or to receive placebo followed by autologous MSCs at week 24, with a follow-up visit at week 48. Primary objectives were to test safety and activity of MSC treatment. The primary safety endpoint was to assess the number and severity of adverse events within each treatment arm. The primary efficacy endpoint was the number of gadolinium-enhancing lesions (GELs) counted over week 4, 12, and 24 compared between treatment groups. The primary efficacy endpoint was assessed in the full analyis set, after all participants completed the week 24 visit. Efficacy endpoints were evaluated using a predefined statistical testing procedure. Safety was monitored throughout the study by recording vital signs and adverse events at each visit. FINDINGS: From July 16, 2012, until July 31, 2019, 144 patients were randomly assigned to first receive early intravenous infusion of autologous bone marrow-derived MSCs (n=69) or placebo (n=75). MSC treatment did not meet the primary endpoint of efficacy on the total number of GELs accumulated from baseline to week 24 (rate ratio [RR] 0·94, 95% CI 0·58-1·50; p=0·78). 213 adverse events were recorded, similarly distributed between groups (93 cases recorded in 35 [51%] of 69 patients treated first with MSCs vs 120 cases in 42 [56%] of 75 patients infused first with placebo). The most frequent adverse events reported were infection and infestations, with a total of 54 (25%) of 213 adverse events (18 [19%] of 93 in the early-MSC group and 36 [30%] of 120 in the delayed-MSC group). Nine serious adverse events were reported in seven patients treated with placebo versus none in the MSC group. All serious adverse events were considered to be unrelated to the treatment infusion. No deaths were reported during the study. INTERPRETATION: Bone marrow-derived MSC treatment was safe and well tolerated but did not show an effect on GELs, an MRI surrogate marker of acute inflammation, in patients with active forms of multiple sclerosis, at week 24. Thus, this study does not support the use of bone marrow-derived MSCs to treat active multiple sclerosis. Further studies should address the effect of MSCs on parameters related to tissue repair. FUNDING: Fondazione Italiana Sclerosi Multipla (FISM), the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), and the Multiple Sclerosis International Federation (MSIF) for centralised activities. Individual trials participating in the MESEMS network are funded by the following agencies: FISM and Compagnia di San Paolo (Italy); The Danish Multiple Sclerosis Society, The Toyota Foundation, and Danish Blood Donors' Research Foundation (Denmark); the Spanish Health Research Institute Carlos 3 and the Andalusian Public Foundation Progreso y Salud (Spain); the Royan Institute for Stem Cell Biology and Technology (Iran); the Spinal Cord Injury and Tissue Regeneration Centre Salzburg, Paracelsus Medical University, and Salzburg (Austria); the Fondation pour l'aide à la recherche sur la sclérose en plaques (ARSEP), French Muscular Dystrophy Association (AFM)-Telethon (France); the UK Multiple Sclerosis Society and the UK Stem Cell Foundation (UK); and the Multiple Sclerosis Society of Canada and The Multiple Sclerosis Scientific Research Foundation and Research Manitoba (Canada).

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Uccelli A, Laroni A, Ali R, et al. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. Lancet Neurol. 2021. PMID: 34687636. doi:10.1016/S1474-4422(21)00301-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。